Statin-induced adverse effects and malignant hyperthermia susceptibility: Comment on the article by Guis et al [2]

Arthritis Care and Research

Volumn 57, Issue 1, 2007, Pages 186-187

  Vladutiu, Georgirene ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CAFFEINE; CREATINE KINASE; HALOTHANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; LETTER; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MYOPATHY; NEUROMUSCULAR DISEASE; RHABDOMYOLYSIS; SIDE EFFECT; SKELETAL MUSCLE;

DISEASE SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALIGNANT HYPERTHERMIA; MUTATION; RHABDOMYOLYSIS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; UBIQUINONE;

EID: 33846972998     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22487     Document Type: Letter

References (7)

1. Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006;55:551-7.
2. Klingler W, Lehmann-Horn F, Jurkat-Rott K. Complications of anaesthesia in neuromuscular disorders [review]. Neuromuscul Disord 2005;15:195-206.
3. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA 2005;293:2918-24.
4. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26.
5. Sei Y, Sambuughin NN, Davis EJ, Sachs D, Cuenca PB, Brandom BW, et al. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004;101:824-30.
6. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-62.
7. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-4.